Ligand to Acquire Ab Initio Biotherapeutics for its Antigen Technology

Shots:

• Ligand will acquire Ab Initio for $12M in cash as Ab Initio’s antigen technology is complimenting Ligand’s OmniAb therapeutic antibody discovery platform which will further strengthen and expand ligand’s OmniAb offerings
• In 2016, Ab Initio and Pfizer collaborated to develop AB against GPCR, post-acquisition Ligand will receive milestones and royalties on sales of targeted Abs  
• Ligand’s OmniAb antibody platform produces naturally optimized human antibodies while Ab Initio’s antigen discovery platform targets multi-transmembrane proteins like GPCRs and advance Ab for multiple therapeutic indications including neurological, cardiovascular, endocrine and gastrointestinal disorders

Click here to read full press release/ article | Ref: Ligand | Image: JLabs